(MENAFN- GlobeNewsWire - Nasdaq) New York, May 25, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Antibacterial Drugs Industry" -
-lactams, one of the segments analyzed in the report, is projected to record a 4.1% CAGR and reach US$35.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Macrolides segment is readjusted to a revised 4.4% CAGR for the next 8-year period.
The U.S. Market is Estimated at $11.8 Billion, While China is Forecast to Grow at 6.5% CAGR
The Antibacterial Drugs market in the U.S. is estimated at US$11.8 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$12.1 Billion by the year 2030 trailing a CAGR of 6.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2% and 3.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$7.8 Billion by the year 2030.
Select Competitors (Total 124 Featured)
- Allergan PLC
- AstraZeneca PLC
- Bayer AG
- Bristol-Myers Squibb Company
- GlaxoSmithKline PLC
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis International AG
- Pfizer, Inc.
Read the full report:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Antibacterial Drugs - Global Key Competitors Percentage Market
Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Antibacterial Drugs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 2: World Historic Review for Antibacterial Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 3: World 16-Year Perspective for Antibacterial Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2014, 2023 & 2030
Table 4: World Recent Past, Current & Future Analysis for
Enteral by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 5: World Historic Review for Enteral by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 6: World 16-Year Perspective for Enteral by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for
Parenteral by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 8: World Historic Review for Parenteral by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 9: World 16-Year Perspective for Parenteral by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030
Table 10: World Recent Past, Current & Future Analysis for
Hospital Pharmacies by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 11: World Historic Review for Hospital Pharmacies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 12: World 16-Year Perspective for Hospital Pharmacies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 13: World Recent Past, Current & Future Analysis for Drug
Stores & Retail Pharmacies by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR
Table 14: World Historic Review for Drug Stores & Retail
Pharmacies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 15: World 16-Year Perspective for Drug Stores & Retail
Pharmacies by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030
Table 16: World Recent Past, Current & Future Analysis for
Online Sales by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 17: World Historic Review for Online Sales by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 18: World 16-Year Perspective for Online Sales by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 19: World Recent Past, Current & Future Analysis for
Other Routes of Administration by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 20: World Historic Review for Other Routes of
Administration by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 21: World 16-Year Perspective for Other Routes of
Administration by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2014, 2023 & 2030
Table 22: World Recent Past, Current & Future Analysis for
-lactams by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 23: World Historic Review for -lactams by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 24: World 16-Year Perspective for -lactams by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030
Table 25: World Recent Past, Current & Future Analysis for
Quinolones by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 26: World Historic Review for Quinolones by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 27: World 16-Year Perspective for Quinolones by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 28: World Recent Past, Current & Future Analysis for
Macrolides by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 29: World Historic Review for Macrolides by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 30: World 16-Year Perspective for Macrolides by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 31: World Recent Past, Current & Future Analysis for
Tetracyclines by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 32: World Historic Review for Tetracyclines by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 33: World 16-Year Perspective for Tetracyclines by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 34: World Recent Past, Current & Future Analysis for
Aminoglycosides by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 35: World Historic Review for Aminoglycosides by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 36: World 16-Year Perspective for Aminoglycosides by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 37: World Recent Past, Current & Future Analysis for
Other Drug Classes by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 38: World Historic Review for Other Drug Classes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 39: World 16-Year Perspective for Other Drug Classes by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 40: World Antibacterial Drugs Market Analysis of Annual
Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Antibacterial Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2023 (E)
Table 41: USA Recent Past, Current & Future Analysis for
Antibacterial Drugs by Route Of Administration - Enteral,
Parenteral and Other Routes of Administration - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 42: USA Historic Review for Antibacterial Drugs by Route
Of Administration - Enteral, Parenteral and Other Routes of
Administration Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2014 through 2021 and % CAGR
Table 43: USA 16-Year Perspective for Antibacterial Drugs by
Route Of Administration - Percentage Breakdown of Value Sales
for Enteral, Parenteral and Other Routes of Administration for
the Years 2014, 2023 & 2030
Table 44: USA Recent Past, Current & Future Analysis for
Antibacterial Drugs by Distribution Channel - Hospital
Pharmacies, Drug Stores & Retail Pharmacies and Online Sales -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 45: USA Historic Review for Antibacterial Drugs by
Distribution Channel - Hospital Pharmacies, Drug Stores &
Retail Pharmacies and Online Sales Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 46: USA 16-Year Perspective for Antibacterial Drugs by
Distribution Channel - Percentage Breakdown of Value Sales for
Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online
Sales for the Years 2014, 2023 & 2030
Table 47: USA Recent Past, Current & Future Analysis for
Antibacterial Drugs by Drug Class - -lactams, Quinolones,
Macrolides, Tetracyclines, Aminoglycosides and Other Drug
Classes - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 48: USA Historic Review for Antibacterial Drugs by Drug
Class - -lactams, Quinolones, Macrolides, Tetracyclines,
Aminoglycosides and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 49: USA 16-Year Perspective for Antibacterial Drugs by
Drug Class - Percentage Breakdown of Value Sales for -lactams,
Quinolones, Macrolides, Tetracyclines, Aminoglycosides and
Other Drug Classes for the Years 2014, 2023 & 2030
CANADA
Table 50: Canada Recent Past, Current & Future Analysis for
Antibacterial Drugs by Route Of Administration - Enteral,
Parenteral and Other Routes of Administration - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 51: Canada Historic Review for Antibacterial Drugs by
Route Of Administration - Enteral, Parenteral and Other Routes
of Administration Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 52: Canada 16-Year Perspective for Antibacterial Drugs by
Route Of Administration - Percentage Breakdown of Value Sales
for Enteral, Parenteral and Other Routes of Administration for
the Years 2014, 2023 & 2030
Table 53: Canada Recent Past, Current & Future Analysis for
Antibacterial Drugs by Distribution Channel - Hospital
Pharmacies, Drug Stores & Retail Pharmacies and Online Sales -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 54: Canada Historic Review for Antibacterial Drugs by
Distribution Channel - Hospital Pharmacies, Drug Stores &
Retail Pharmacies and Online Sales Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 55: Canada 16-Year Perspective for Antibacterial Drugs by
Distribution Channel - Percentage Breakdown of Value Sales for
Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online
Sales for the Years 2014, 2023 & 2030
Table 56: Canada Recent Past, Current & Future Analysis for
Antibacterial Drugs by Drug Class - -lactams, Quinolones,
Macrolides, Tetracyclines, Aminoglycosides and Other Drug
Classes - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 57: Canada Historic Review for Antibacterial Drugs by
Drug Class - -lactams, Quinolones, Macrolides, Tetracyclines,
Aminoglycosides and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 58: Canada 16-Year Perspective for Antibacterial Drugs by
Drug Class - Percentage Breakdown of Value Sales for -lactams,
Quinolones, Macrolides, Tetracyclines, Aminoglycosides and
Other Drug Classes for the Years 2014, 2023 & 2030
JAPAN
Antibacterial Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2023 (E)
Table 59: Japan Recent Past, Current & Future Analysis for
Antibacterial Drugs by Route Of Administration - Enteral,
Parenteral and Other Routes of Administration - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 60: Japan Historic Review for Antibacterial Drugs by
Route Of Administration - Enteral, Parenteral and Other Routes
of Administration Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 61: Japan 16-Year Perspective for Antibacterial Drugs by
Route Of Administration - Percentage Breakdown of Value Sales
for Enteral, Parenteral and Other Routes of Administration for
the Years 2014, 2023 & 2030
Table 62: Japan Recent Past, Current & Future Analysis for
Antibacterial Drugs by Distribution Channel - Hospital
Pharmacies, Drug Stores & Retail Pharmacies and Online Sales -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 63: Japan Historic Review for Antibacterial Drugs by
Distribution Channel - Hospital Pharmacies, Drug Stores &
Retail Pharmacies and Online Sales Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 64: Japan 16-Year Perspective for Antibacterial Drugs by
Distribution Channel - Percentage Breakdown of Value Sales for
Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online
Sales for the Years 2014, 2023 & 2030
Table 65: Japan Recent Past, Current & Future Analysis for
Antibacterial Drugs by Drug Class - -lactams, Quinolones,
Macrolides, Tetracyclines, Aminoglycosides and Other Drug
Classes - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 66: Japan Historic Review for Antibacterial Drugs by Drug
Class - -lactams, Quinolones, Macrolides, Tetracyclines,
Aminoglycosides and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 67: Japan 16-Year Perspective for Antibacterial Drugs by
Drug Class - Percentage Breakdown of Value Sales for -lactams,
Quinolones, Macrolides, Tetracyclines, Aminoglycosides and
Other Drug Classes for the Years 2014, 2023 & 2030
CHINA
Antibacterial Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2023 (E)
Table 68: China Recent Past, Current & Future Analysis for
Antibacterial Drugs by Route Of Administration - Enteral,
Parenteral and Other Routes of Administration - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 69: China Historic Review for Antibacterial Drugs by
Route Of Administration - Enteral, Parenteral and Other Routes
of Administration Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 70: China 16-Year Perspective for Antibacterial Drugs by
Route Of Administration - Percentage Breakdown of Value Sales
for Enteral, Parenteral and Other Routes of Administration for
the Years 2014, 2023 & 2030
Table 71: China Recent Past, Current & Future Analysis for
Antibacterial Drugs by Distribution Channel - Hospital
Pharmacies, Drug Stores & Retail Pharmacies and Online Sales -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 72: China Historic Review for Antibacterial Drugs by
Distribution Channel - Hospital Pharmacies, Drug Stores &
Retail Pharmacies and Online Sales Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 73: China 16-Year Perspective for Antibacterial Drugs by
Distribution Channel - Percentage Breakdown of Value Sales for
Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online
Sales for the Years 2014, 2023 & 2030
Table 74: China Recent Past, Current & Future Analysis for
Antibacterial Drugs by Drug Class - -lactams, Quinolones,
Macrolides, Tetracyclines, Aminoglycosides and Other Drug
Classes - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 75: China Historic Review for Antibacterial Drugs by Drug
Class - -lactams, Quinolones, Macrolides, Tetracyclines,
Aminoglycosides and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 76: China 16-Year Perspective for Antibacterial Drugs by
Drug Class - Percentage Breakdown of Value Sales for -lactams,
Quinolones, Macrolides, Tetracyclines, Aminoglycosides and
Other Drug Classes for the Years 2014, 2023 & 2030
EUROPE
Antibacterial Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2023 (E)
Table 77: Europe Recent Past, Current & Future Analysis for
Antibacterial Drugs by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR
Table 78: Europe Historic Review for Antibacterial Drugs by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 79: Europe 16-Year Perspective for Antibacterial Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2014, 2023 & 2030
Table 80: Europe Recent Past, Current & Future Analysis for
Antibacterial Drugs by Route Of Administration - Enteral,
Parenteral and Other Routes of Administration - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 81: Europe Historic Review for Antibacterial Drugs by
Route Of Administration - Enteral, Parenteral and Other Routes
of Administration Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 82: Europe 16-Year Perspective for Antibacterial Drugs by
Route Of Administration - Percentage Breakdown of Value Sales
for Enteral, Parenteral and Other Routes of Administration for
the Years 2014, 2023 & 2030
Table 83: Europe Recent Past, Current & Future Analysis for
Antibacterial Drugs by Distribution Channel - Hospital
Pharmacies, Drug Stores & Retail Pharmacies and Online Sales -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 84: Europe Historic Review for Antibacterial Drugs by
Distribution Channel - Hospital Pharmacies, Drug Stores &
Retail Pharmacies and Online Sales Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 85: Europe 16-Year Perspective for Antibacterial Drugs by
Distribution Channel - Percentage Breakdown of Value Sales for
Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online
Sales for the Years 2014, 2023 & 2030
Table 86: Europe Recent Past, Current & Future Analysis for
Antibacterial Drugs by Drug Class - -lactams, Quinolones,
Macrolides, Tetracyclines, Aminoglycosides and Other Drug
Classes - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 87: Europe Historic Review for Antibacterial Drugs by
Drug Class - -lactams, Quinolones, Macrolides, Tetracyclines,
Aminoglycosides and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 88: Europe 16-Year Perspective for Antibacterial Drugs by
Drug Class - Percentage Breakdown of Value Sales for -lactams,
Quinolones, Macrolides, Tetracyclines, Aminoglycosides and
Other Drug Classes for the Years 2014, 2023 & 2030
FRANCE
Antibacterial Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2023 (E)
Table 89: France Recent Past, Current & Future Analysis for
Antibacterial Drugs by Route Of Administration - Enteral,
Parenteral and Other Routes of Administration - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 90: France Historic Review for Antibacterial Drugs by
Route Of Administration - Enteral, Parenteral and Other Routes
of Administration Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 91: France 16-Year Perspective for Antibacterial Drugs by
Route Of Administration - Percentage Breakdown of Value Sales
for Enteral, Parenteral and Other Routes of Administration for
the Years 2014, 2023 & 2030
Table 92: France Recent Past, Current & Future Analysis for
Antibacterial Drugs by Distribution Channel - Hospital
Pharmacies, Drug Stores & Retail Pharmacies and Online Sales -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 93: France Historic Review for Antibacterial Drugs by
Distribution Channel - Hospital Pharmacies, Drug Stores &
Retail Pharmacies and Online Sales Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 94: France 16-Year Perspective for Antibacterial Drugs by
Distribution Channel - Percentage Breakdown of Value Sales for
Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online
Sales for the Years 2014, 2023 & 2030
Table 95: France Recent Past, Current & Future Analysis for
Antibacterial Drugs by Drug Class - -lactams, Quinolones,
Macrolides, Tetracyclines, Aminoglycosides and Other Drug
Classes - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 96: France Historic Review for Antibacterial Drugs by
Drug Class - -lactams, Quinolones, Macrolides, Tetracyclines,
Aminoglycosides and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 97: France 16-Year Perspective for Antibacterial Drugs by
Drug Class - Percentage Breakdown of Value Sales for -lactams,
Quinolones, Macrolides, Tetracyclines, Aminoglycosides and
Other Drug Classes for the Years 2014, 2023 & 2030
GERMANY
Antibacterial Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2023 (E)
Table 98: Germany Recent Past, Current & Future Analysis for
Antibacterial Drugs by Route Of Administration - Enteral,
Parenteral and Other Routes of Administration - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 99: Germany Historic Review for Antibacterial Drugs by
Route Of Administration - Enteral, Parenteral and Other Routes
of Administration Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 100: Germany 16-Year Perspective for Antibacterial Drugs
by Route Of Administration - Percentage Breakdown of Value
Sales for Enteral, Parenteral and Other Routes of
Administration for the Years 2014, 2023 & 2030
Table 101: Germany Recent Past, Current & Future Analysis for
Antibacterial Drugs by Distribution Channel - Hospital
Pharmacies, Drug Stores & Retail Pharmacies and Online Sales -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 102: Germany Historic Review for Antibacterial Drugs by
Distribution Channel - Hospital Pharmacies, Drug Stores &
Retail Pharmacies and Online Sales Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 103: Germany 16-Year Perspective for Antibacterial Drugs
by Distribution Channel - Percentage Breakdown of Value Sales
for Hospital Pharmacies, Drug Stores & Retail Pharmacies and
Online Sales for the Years 2014, 2023 & 2030
Table 104: Germany Recent Past, Current & Future Analysis for
Antibacterial Drugs by Drug Class - -lactams, Quinolones,
Macrolides, Tetracyclines, Aminoglycosides and Other Drug
Classes - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 105: Germany Historic Review for Antibacterial Drugs by
Drug Class - -lactams, Quinolones, Macrolides, Tetracyclines,
Aminoglycosides and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 106: Germany 16-Year Perspective for Antibacterial Drugs
by Drug Class - Percentage Breakdown of Value Sales for
-lactams, Quinolones, Macrolides, Tetracyclines,
Aminoglycosides and Other Drug Classes for the Years 2014, 2023 &
2030
ITALY
Table 107: Italy Recent Past, Current & Future Analysis for
Antibacterial Drugs by Route Of Administration - Enteral,
Parenteral and Other Routes of Administration - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 108: Italy Historic Review for Antibacterial Drugs by
Route Of Administration - Enteral, Parenteral and Other Routes
of Administration Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 109: Italy 16-Year Perspective for Antibacterial Drugs by
Route Of Administration - Percentage Breakdown of Value Sales
for Enteral, Parenteral and Other Routes of Administration for
the Years 2014, 2023 & 2030
Table 110: Italy Recent Past, Current & Future Analysis for
Antibacterial Drugs by Distribution Channel - Hospital
Pharmacies, Drug Stores & Retail Pharmacies and Online Sales -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 111: Italy Historic Review for Antibacterial Drugs by
Distribution Channel - Hospital Pharmacies, Drug Stores &
Retail Pharmacies and Online Sales Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 112: Italy 16-Year Perspective for Antibacterial Drugs by
Distribution Channel - Percentage Breakdown of Value Sales for
Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online
Sales for the Years 2014, 2023 & 2030
Table 113: Italy Recent Past, Current & Future Analysis for
Antibacterial Drugs by Drug Class - -lactams, Quinolones,
Macrolides, Tetracyclines, Aminoglycosides and Other Drug
Classes - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 114: Italy Historic Review for Antibacterial Drugs by
Drug Class - -lactams, Quinolones, Macrolides, Tetracyclines,
Aminoglycosides and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 115: Italy 16-Year Perspective for Antibacterial Drugs by
Drug Class - Percentage Breakdown of Value Sales for -lactams,
Quinolones, Macrolides, Tetracyclines, Aminoglycosides and
Other Drug Classes for the Years 2014, 2023 & 2030
UNITED KINGDOM
Antibacterial Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2023 (E)
Table 116: UK Recent Past, Current & Future Analysis for
Antibacterial Drugs by Route Of Administration - Enteral,
Parenteral and Other Routes of Administration - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 117: UK Historic Review for Antibacterial Drugs by Route
Of Administration - Enteral, Parenteral and Other Routes of
Administration Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2014 through 2021 and % CAGR
Table 118: UK 16-Year Perspective for Antibacterial Drugs by
Route Of Administration - Percentage Breakdown of Value Sales
for Enteral, Parenteral and Other Routes of Administration for
the Years 2014, 2023 & 2030
Table 119: UK Recent Past, Current & Future Analysis for
Antibacterial Drugs by Distribution Channel - Hospital
Pharmacies, Drug Stores & Retail Pharmacies and Online Sales -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 120: UK Historic Review for Antibacterial Drugs by
Distribution Channel - Hospital Pharmacies, Drug Stores &
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report:
About reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
